Annals of Oncology Advance Access originally published online on March 28, 2008
Annals of Oncology 2008 19(6):1203; doi:10.1093/annonc/mdn152
© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letters |
How can we use anthracylines in the management of newly diagnosed metastatic breast cancer patients overexpressing HER-2?
| The first 10% of the full text of this article appears below. |
Most women who have metastatic breast cancer (MBC) have had early-stage breast cancer. Therefore, many of them received adjuvant treatment including anthracylines. Starting off
Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey
* (E-mail: altundag66@yahoo.com)